The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) with the corresponding natural killer group 2, member D (NKG2D) receptor triggers cytotoxic effector activity of natural killer cells and certain T-cell subsets and provides a costimulatory signal for cytokine production. Thus, the presence of MICA=B on transformed cells contributes to tumor immunosurveillance. Consequently, the proteolytic cleavage of MICA=B is regarded as an important immune escape mechanism of various cancer cells. To investigate the molecular machinery responsible for the shedding of endogenous MICA=B, we analyzed different human tumor entities including mammary, pancreatic and prostate carcinomas. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) revealed that all tested tumor cells constitutively expressed MICA and MICB on the cell surface and also released NKG2D ligands into the supernatant. We demonstrate that the "a disintegrin and metalloproteases" (ADAMs) 10 and 17 are largely responsible for the generation of soluble MICA=B. Pharmacological inhibition of metalloproteases reduced the level of released MICA=B and increased cell surface expression. Studies using RNA interference not only revealed a prominent role of ADAM10 and ADAM17 in NKG2D ligand shedding but also a tumor cell-specific role of ADAM10 and=or ADAM17 in shedding of MICA or MICB. Moreover, we report that in the prostate carcinoma cell line PC-3, MICA was not shed at all but rather was secreted in exosomes. These data indicate that the release of NKG2D ligands from individual tumor entities is by far more complex than suggested in previously reported MICA=B transfection systems.The activating natural killer group 2, member D (NKG2D) receptor is expressed on NK cells, NKT cells, gd T cells, CD8 1 T cells and a minor immunoregulatory subset of CD4 1 T cells. 1,2 The ligation of NKG2D costimulates T cells but also directly triggers cell-mediated cytotoxicity and cytokine release in NK cells. [3][4][5][6] Thus, despite some exceptions including gastrointestinal epithelium 7 and placenta, 8 the ligands for NKG2D are not expressed on healthy tissues to avoid inadvertent damage. However, NKG2D ligand (NKG2DL) expression can be induced in response to a variety of stimuli related to cellular stress such as heat shock, viral infection, DNA damage, oxidative stress and certain proinflammatory signals. 9,10 Of note, many tumors and precancerous lesions express NKG2D ligands presumably as a bystander effect of the oncogenic process itself. 11 As NKG2DL expression renders tumors susceptible to NKG2D 1 lymphocytes, the NKG2D system plays a pivotal role in immunosurveillance. 12 On the other hand, the sustained exposure to tumor cell-bound NKG2D ligands might also result in surface modulation and functional impairment of the NKG2D receptor and induce cross-tolerance of additional NK cell activation pathways. 13,14 A hallmark of the NKG2D system is the multitude of ligands identified so far. In humans, these include the MHC class I-related chain ...
The activating natural killer group 2 member D (NKG2D) receptor is expressed on NK cells, cytotoxic T cells and additional T cell subsets. Ligands for human NKG2D comprise two groups of MHC class I-related molecules, the MHC class I chain-related proteins A and B (MICA/B) and 6 UL16-binding proteins (ULBP1-6). While NKG2D ligands are absent from most normal cells, expression is induced upon stress and malignant transformation. In fact, most solid tumours and leukaemia/lymphomas constitutively express at least one NKG2D ligand and thereby are susceptible to NKG2D-dependent immunosurveillance. However, soluble NKG2D ligands are released from tumour cells and can down-modulate NKG2D activation as a means of tumour immune escape. In some tumour entities, levels of soluble NKG2D ligands in the serum correlate with tumour progression. NKG2D ligands can be proteolytically shed from the cell surface or liberated from the membrane by phospholipase C in the case of glycosylphosphatidylinositol (GPI)-anchored molecules. Moreover, NKG2D ligands can be secreted in exosomal microvesicles together with other tumour-derived molecules. Depending on the specific tumour/immune cell setting, these various forms of soluble and/or exosome-bound NKG2D ligands can exert multiple effects on NKG2D/NKG2D ligand interactions. In this review, we focus on the role of various proteases in the shedding of human NKG2D ligands from tumour cells and discuss the not completely unanimous reported functional implications of soluble and exosome-secreted NKG2D ligands for immunosurveillance.
Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy. Immunological mechanisms including the Natural Killer Group 2 member D (NKG2D) receptor-ligand system play an important role in tumor immune surveillance and targeting the NKG2D system might be beneficial. However, before considering any kind of immunotherapy, a precise characterization of the immune system is important, particularly in GBM patients where conventional therapies with impact on the immune system are frequently co-administered. Here we performed an in-depth immunophenotyping of GBM patients and age-matched healthy controls and analyzed NKG2D ligand expression on primary GBM cells . We report that GBM patients have a compromised innate immune system irrespective of steroid (dexamethasone) medication. However, dexamethasone drastically reduced the number of immune cells in the blood of GBM patients. Moreover, higher counts of immune cells influenced by dexamethasone like CD45 lymphocytes and non-Vδ2 γδ T cells were associated with better overall survival. Higher levels of NKG2D ligands on primary GBM tumor cells were observed in patients who received radiochemotherapy, pointing towards increased immunogenic potential of GBM cells following standard radiochemotherapy. This study sheds light on how steroids and radiochemotherapy affect immune cell parameters of GBM patients, a pre-requisite for the development of new therapeutic strategies targeting the immune system in these patients.
Human γδ T cells are potent cytotoxic effector cells, produce a variety of cytokines, and can acquire regulatory activity. Induction of FOXP3, the key transcription factor of regulatory T cells (Treg), by TGF-β in human Vγ9 Vδ2 T cells has been previously reported. Vitamin C is an antioxidant and acts as multiplier of DNA hydroxymethylation. Here we have investigated the effect of the more stable phospho-modified Vitamin C (pVC) on TGF-β-induced FOXP3 expression and the resulting regulatory activity of highly purified human Vγ9 Vδ2 T cells. pVC significantly increased the TGF-β-induced FOXP3 expression and stability and also increased the suppressive activity of Vγ9 Vδ2 T cells. Importantly, pVC induced hypomethylation of the Treg-specific demethylated region (TSDR) in the FOXP3 gene. Genome-wide methylation analysis by Reduced Representation Bisulfite Sequencing additionally revealed differentially methylated regions in several important genes upon pVC treatment of γδ t cells. While Vitamin C also enhances effector functions of Vγ9 Vδ2 T cells in the absence of TGF-β, our results demonstrate that pVC potently increases the suppressive activity and FOXP3 expression in TGF-βtreated Vγ9 Vδ2 T cells by epigenetic modification of the FOXP3 gene. Most T cells express the αβ T-cell receptor (TCR) which serves to recognize peptides presented by MHC/HLA class I or class II molecules to CD8 T cells or CD4 T cells, respectively. The germline TCR repertoire of αβ T cells is highly diverse, due to the large number of available variable (V) Vα and Vβ elements that can be selected during TCR gene rearrangement. By contrast, only a few Vγ and Vδ germline gene elements are available for the recombination of functional human γδ TCR 1. γδ T cells comprise 2-5% of peripheral blood T cells but are enriched in mucosal tissue. In human peripheral blood, the majority of γδ T cells expresses a Vγ9 Vδ2 TCR, whereas Vδ1 associated with various Vγ elements is predominantly expressed by intestinal γδ T cells 2,3. Vγ9 Vδ2 T cells recognize pyrophosphate molecules ("phosphoantigens", pAg) which are intermediates of the eukaryotic mevalonate or the prokaryotic non-mevalonate pathway of isoprenoid biosynthesis 4. Prototypes of such pAg are the eukaryotic isopentenyl pyrophosphate (IPP) and the prokaryotic (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) which selectively activate Vγ9 Vδ2 T cells at micro-and nanomolar concentrations, respectively 4,5. Synthetic analogs of naturally occurring pAg like bromohydrin pyrophosphate (BrHPP) have been described, exerting potent and selective stimulation of human Vγ9 Vδ2 T cells 6. While activation of Vγ9 Vδ2 T cells by pAg does not require HLA class I or class II molecules, there is an indispensable requirement for the transmembrane protein butyrophilin 3 A (BTN3A/CD277) 7. The current model implies that pAg bind to the intracellular B30.2 domain of BTN3A, thereby initiating a conformational change of the extracellular domain which is then selectively sensed by the Vγ9 Vδ2 TCR 8. Activated Vγ9 V...
γδ T cell-based immunotherapeutic strategies in cancer patients are as yet of limited success. Drugs targeting epigenetic mechanisms including histone acetylation and DNA methylation trigger cell death in tumor cells but in addition have immunomodulatory activity. Here, we discuss the potential benefit of combining both strategies in cancer immunotherapy.
The functional plasticity and anti-tumor potential of human γδ T cells have been widely studied. However, the epigenetic regulation of γδ T-cell/tumor cell interactions has been poorly investigated. In the present study, we show that treatment with the histone deacetylase inhibitor Valproic acid (VPA) significantly enhanced the expression and/or release of the NKG2D ligands MICA, MICB and ULBP-2, but not ULBP-1 in the pancreatic carcinoma cell line Panc89 and the prostate carcinoma cell line PC-3. Under in vitro tumor co-culture conditions, the expression of full length and the truncated form of the NKG2D receptor in γδ T cells was significantly downregulated. Furthermore, using a newly established flow cytometry-based method to analyze histone acetylation (H3K9ac) in γδ T cells, we showed constitutive H3K9ac low and inducible H3K9ac high expression in Vδ2 T cells. The detailed analysis of H3K9ac low Vδ2 T cells revealed a significant reversion of T EMRA to T EM phenotype during in vitro co-culture with pancreatic ductal adenocarcinoma cells. Our study uncovers novel mechanisms of how epigenetic modifiers modulate γδ T-cell differentiation during interaction with tumor cells. This information is important when considering combination therapy of VPA with the γδ T-cell-based immunotherapy for the treatment of certain types of cancer.
Previously, the expression of a non-secreted IL-4 variant (IL-4δ13) has been described in association with apoptosis and age-dependent Th2 T-cell polarization. Signaling pathways involved in this process have so far not been studied. Here we report the induction of IL-4δ13 expression in human γδ T-cells upon treatment with a sublethal dose of histone deacetylase (HDACi) inhibitor valproic acid (VPA). Induction of IL-4δ13 was associated with increased cytoplasmic IL-4Rα and decreased IL-4 expression, while mRNA for mature IL-4 was concomitantly down-regulated. Importantly, only the simultaneous combination of apoptosis and necroptosis inhibitors prevented IL-4δ13 expression and completely abrogated VPA-induced global histone H3K9 acetylation mark. Further, our work reveals a novel involvement of transcription factor c-Jun in the signaling network of IL-4, HDAC1, caspase-3 and mixed lineage kinase domain-like protein (MLKL). This study provides novel insights into the effects of epigenetic modulator VPA on human γδ T-cell differentiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.